{"transactions":[{"id":1637640,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025."}],"balance_after":350000,"derivative":{"exercise_price":1.92,"expiration_date":"2032-08-25","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637639,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025."}],"balance_after":0,"derivative":{"exercise_price":2.54,"expiration_date":"2032-08-25","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637638,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":2000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024."}],"balance_after":2000000,"derivative":{"exercise_price":1.92,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637637,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.57,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637636,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":450000,"derivative":{"exercise_price":1.92,"exercise_date":"2024-02-13","expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637635,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2021-06-11","expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637634,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":300000,"derivative":{"exercise_price":1.92,"exercise_date":"2024-02-13","expiration_date":"2028-11-21","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637633,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":0,"derivative":{"exercise_price":6.5,"exercise_date":"2018-11-21","expiration_date":"2028-11-21","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637632,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":5226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":5226,"derivative":{"exercise_price":1.92,"exercise_date":"2024-02-13","expiration_date":"2028-09-19","underlying":"Common Stock","underlying_shares":5226},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637631,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":0,"derivative":{"exercise_price":5.74,"exercise_date":"2019-02-28","expiration_date":"2028-09-19","underlying":"Common Stock","underlying_shares":5226},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637630,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":7563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."}],"balance_after":7563,"derivative":{"exercise_price":1.92,"exercise_date":"2024-02-13","expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":7563},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":1637629,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-16T14:06:47.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a stock option repricing (the \"Option Repricing\") effective on February 13, 2024 (the \"Repricing Date\"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021."}],"balance_after":0,"derivative":{"exercise_price":5.95,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":7563},"source":{"system":"sec-edgar","filing":"0001731122-24-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000263/ownership.xml","form_type":"4"}},{"id":2158198,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase shares of common stock","published_at":"2022-09-15T16:36:16.000Z","date":"2022-08-25","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest ratably on August 25, 2023, August 25, 2024 and August 25, 2025."}],"balance_after":350000,"derivative":{"exercise_price":2.54,"expiration_date":"2032-08-25","underlying":"Common stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001731122-22-001581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112222001581/ownership.xml","form_type":"4"}},{"id":2626975,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase shares of common stock","published_at":"2021-07-22T20:33:09.000Z","date":"2021-07-19","kind":"grant","acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest ratably on July 1, 2022, July 1, 2023 and July 1, 2024."}],"balance_after":2000000,"derivative":{"exercise_price":4.57,"expiration_date":"2031-07-19","underlying":"Common stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001731122-21-001219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112221001219/ownership.xml","form_type":"4"}},{"id":2941947,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice Chair"}}],"security":"Common Stock","published_at":"2020-12-16T19:03:09.000Z","date":"2020-12-14","kind":"other","acquired":true,"shares":180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On December 14, 2020, Mark Dybul received 180 shares of common stock pursuant to a contractual right to receive shares upon the exercise of outstanding warrants of the Issuer."}],"balance_after":66196,"source":{"system":"sec-edgar","filing":"0001731122-20-001305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112220001305/ownership.xml","form_type":"4"}},{"id":3104011,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice Chair"}}],"security":"Option to Purchase Common Stock","published_at":"2020-06-19T19:01:56.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":450000,"derivative":{"exercise_price":8,"exercise_date":"2021-06-11","expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001731122-20-000662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112220000662/ownership.xml","form_type":"4"}},{"id":3450552,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice Chair"}}],"security":"Common Stock","published_at":"2019-08-02T01:28:23.000Z","date":"2019-07-30","kind":"other","acquired":true,"shares":10680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 30, 2019, Mark Dybul, M.D. received 10,680 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by warrant holders of the Issuer."}],"balance_after":66016,"source":{"system":"sec-edgar","filing":"0001731122-19-000424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112219000424/ownership.xml","form_type":"4"}},{"id":3707554,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice Chair"}}],"security":"Common Stock","published_at":"2019-01-04T02:44:13.000Z","date":"2018-12-31","kind":"other","acquired":true,"shares":3732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On December 31, 2018, Mark Dybul received 3,732 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by RS Bio ApS."}],"balance_after":55336,"source":{"system":"sec-edgar","filing":"0001731122-19-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112219000008/ownership.xml","form_type":"4"}},{"id":3739057,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-12-07T18:46:44.000Z","date":"2018-11-21","kind":"grant","acquired":true,"shares":300000,"price":6.5,"value":1950000.0,"ownership":{"direct":true},"balance_after":312834,"derivative":{"exercise_price":6.5,"exercise_date":"2018-11-21","expiration_date":"2018-11-21","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001731122-18-000180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112218000180/ownership.xml","form_type":"4"}},{"id":3806425,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":94208,"kind":"person","name":"Dybul Mark","position":1,"cik":"0001734805","reported_name":"Dybul Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-09-27T17:04:09.000Z","date":"2018-09-19","kind":"grant","acquired":true,"shares":5226,"price":5.74,"value":29997.24,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On September 19, 2018, Dr. Dybul was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Dr. Dybul's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant."}],"balance_after":12834,"derivative":{"exercise_price":5.74,"exercise_date":"2019-02-28","expiration_date":"2028-09-19","underlying":"Common Stock","underlying_shares":5226},"source":{"system":"sec-edgar","filing":"0001731122-18-000087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112218000087/ownership.xml","form_type":"4"}}]}